Recruiting Neutrophils with IgA and CD47 Modification to Treat CancerMonday, 28 October 2019 at 14:45 Add to Calendar ▼2019-10-28 14:45:002019-10-28 15:45:00Europe/LondonRecruiting Neutrophils with IgA and CD47 Modification to Treat CancerImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com IgA is a strong activator of neutrophils to kill cancer cells. CD47 is a 'don't eat me' signal for cancer cells and healthy cells, that binds to SIRPalpha on neutrophils as an inhibitory receptor or an innate checkpoint molecule. CD47 can be manipulated to not bind to SIRPalpha anymore, and this strongly enhances the IgA anti-tumor effect in vitro and in vivo (Nature Medicine, in press). |